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Protocol
AbstrACt
Introduction Approximately 1.4%–2.2% of the global 
population suffers from chronic migraine. Acupuncture 
may serve as an alternative management for chronic 
migraine, where pharmacological prophylaxis is not 
suitable. However, the effects of acupuncture as migraine 
prophylaxis have not been confirmed. This study is 
designed as a single-blinded, double-dummy randomised 
controlled trial to evaluate the efficacy and safety of 
acupuncture compared with topiramate in patients with 
chronic migraine.
Methods and analysis A total of 60 participants will be 
randomly assigned to two different groups. Participants 
will receive verum acupuncture and placebo medicine in 
the treatment group, while participants in the control group 
will be treated with sham acupuncture and real medicine 
(topiramate). All participants will receive a 12-week 
treatment and then be followed up for another 12 weeks. 
The primary outcome is the reduction of monthly headache 
days, and the secondary outcomes include the reduction 
of the number of days with acute headache medications, 
and changes of Migraine Disability Assessment, Migraine-
Specific Quality of Life Questionnaire, Headache Impact 
Test, State-Trait Anxiety Inventory-trait, and Beck 
Depression Inventory-II scores from baseline to endpoints.
Ethics and dissemination Ethical approval of this 
study was granted by the Research Ethical Committee of 
Beijing Hospital of Traditional Chinese Medicine Affiliated 
to Capital Medical University (2017BL-045-01). Written 
informed consent will be obtained from all participants. 
Outcomes of the trial will be disseminated through peer-
reviewed publications.
trial registration number ISRCTN13563102; Pre-results.
IntroduCtIon 
Migraine is a highly prevalent neurological 
disorder considered to be the second largest 
contributor to worldwide disability.1 Migraine 
is considered to be a self-limited episodic pain 
disorder, with a growing acknowledgement 
that chronic migraine is in fact the end-stage 
consequence of uncontrolled or poorly 
controlled episodic migraine.2 3 According to 
the International Classification of Headache 
Disorders-Third Edition (beta version) 
(ICHD-IIIβ) from the International Head-
ache Society, chronic migraine is defined 
as ‘headache lasting more than four hours 
each day for more than 15 days per month 
and for at least three months, with at least 
eight days of headache meeting diagnostic 
criteria for episodic migraine’.4 Primary 
chronic migraine is rare; previous research 
has suggested that chronic migraine usually 
evolves from episodic migraine that gradually 
increases in attack frequency, with an annual 
progression rate of approximately 3%.5 6 The 
prevalence of chronic migraine is usually 
reported to be 1%–2% in the general popula-
tion,7–9 and approximately 8% among individ-
uals with migraine.7 Compared with episodic 
migraine, chronic migraine is characterised 
strengths and limitations of this study
 ► This study adopts needling ineffective acupuncture 
points as a sham acupuncture intervention to mini-
mise performance bias.
 ► This study uses a double-dummy design in order 
to blind all patients, rule out the placebo effect and 
make treatments of both groups possibly effective to 
ensure a better compliance of participants.
 ► This study will use topiramate as the standard drug 
therapy in the control group, which is a widely ac-
cepted treatment for chronic migraine prevention; 
this study will use eight main and two additional 
acupuncture points in the treatment group based on 
the concept of a combination of standardised and 
individualised acupuncture treatment.
 ► This study uses comprehensive outcome measures, 
including number of monthly headache days, acute 
headache medications, migraine-related disability, 
quality of life measures and psychological distress.
 ► One potential limitation is that the placebo effects 
on patients produced by placebo drug and sham 
acupuncture may be different due to their different 
non-specific effects.
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by a stronger symptom intensity with longer duration and 
may cause more severe disability. Chronic migraine is also 
associated with a significantly greater degree of health-
care burden and psychiatric comorbidity, such as depres-
sion and anxiety.10–12 
The conversion from episodic to chronic migraine is 
related to the overuse of acute migraine medication,3 13 
ineffective treatment of acute migraine,14 obesity,15 depres-
sion16 and stressful life events, such as divorce or being 
recently widowed.5 Among them, the overuse of acute 
migraine medication is considered to be the most 
important risk factor. The underlying physiological mech-
anisms of the transformation into chronic migraine have 
not been fully discovered, although the roles of atypical 
pain processing, central sensitisation, cortical hyperexcit-
ability and neurogenic inflammation have been studied. 
Furthermore, central sensitisation is assumed to be one 
of the key mechanisms of migraine chronification. Recur-
rent migraine attacks are considered to lead to sensitisa-
tion processes of the trigeminal system, which results in 
an increased susceptibility to migraine-triggering factors, 
a reduced threshold for activation of this system and 
transformation to chronic migraine.17
Once chronic migraine is established, to identify an 
effective treatment is challenging. The options available 
for the treatment of chronic migraine include standard 
pharmacological treatment with migraine prophylactic 
drugs, injections with botulinum neurotoxin A, as well as 
invasive and non-invasive neuromodulation and neuro-
stimulation therapies.18 Notably, once a migraine attack 
has begun, pain killers or specific headache medication 
should be avoided to be used as the sole treatment since 
they will not relieve symptoms, and medication- overuse 
headache may develop due to continuous intake of these 
medications. Instead, the treatment for chronic migraine 
should aim for effective prevention of migraine attacks. 
In this regard, the current standard preventive treatments 
include topiramate, beta-blockers and valproate. Topi-
ramate has been evaluated by multiple double-blinded 
randomised controlled trials (RCT) as a preventive medi-
cation for migraine attacks.
The use of topiramate can effectively reduce head-
ache days,19 improve patients’ quality of life,20 prevent 
the progression from episodic to chronic migraine21 
and induce remission from chronic to episodic 
migraine.22 Adverse events (AE) which include paraes-
thesia, cognitive problems, dyspepsia, fatigue, dizziness, 
somnolence and nausea have been reported during the 
titration and maintenance period of using topiramate.23 
In addition, some patients with chronic migraine do not 
respond to preventive medications,17 hence other alter-
native non-pharmacological therapies are still in need.
Acupuncture has been used for over 2500 years in 
China as an effective non-pharmacologic management 
for headache, including migraine,24–32 but clinical 
evidence on its efficacy in chronic migraine prevention 
is limited. Upon review of the evidence for the efficacy 
of acupuncture in chronic migraine, only one published 
RCT was found, which concluded that acupuncture was 
more effective than topiramate in reducing the number 
of monthly moderate/severe headache days.33 However, 
this study was designed as an open-label clinical trial in 
which neither the researchers nor the participants were 
blinded. The effectiveness shown by this study may have 
been influenced by the lack of blinding. Therefore, we 
designed an RCT involving a placebo control to ensure 
participants’ blinding to investigate the efficacy and safety 
of acupuncture treatment as prophylaxis for chronic 
migraine.
MEthods And AnAlysIs
study design
This trial is designed as a single-blinded, double-dummy 
RCT to evaluate the efficacy of acupuncture compared 
with topiramate in patients with chronic migraine. Sixty 
participants with chronic migraine will be randomly 
assigned to the treatment group and control group at a 
1:1 ratio. The schedule of enrolment, interventions and 
assessments is summarised in table 1 (online supple-
mentary file 1), and the flow diagram of the study proce-
dure is presented in figure 1. Patients’ recruiting is from 
December 2017.
recruitment
Trial participants with chronic migraine are being 
recruited by clinicians from outpatient clinics at the 
Beijing Hospital of Traditional Chinese Medicine Affili-
ated to Capital Medical University. Meanwhile, informa-
tion flyers introducing the details of the trial are being 
posted at the outpatient clinics for greater exposure.
study procedure
This study consists of three phases including: (1) a 4-week 
screening phase (week −4 to week 0); (2) a 12-week 
treatment phase (week 1 to week 12); and (3) a 12-week 
follow-up phase (week 12 to week 24).
Once potential participants show interest in this trial, 
they will be requested to continually record their head-
ache symptoms using a headache diary for 4 weeks, as 
well as their medical history in a screening form. Then 
they will be invited to attend an eligibility assessment in 
which their eligibility will be assessed by trial investiga-
tors; thereafter, eligible participants will be enrolled and 
randomly assigned to either the treatment group or the 
control group and given a 12-week treatment. During the 
treatment phase, medication dosages will be titrated for 
4 weeks, and then followed by a maintenance dosage for 
8 weeks.
Participants
Inclusion criteria
Participants who meet all of the following requirements 
will be considered for inclusion: (1) diagnosed as having 
chronic migraine according to the diagnostic criteria 
specified by the ICHD-IIIβ4; (2) aged between 18 and 65 
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years old; (3) received no prophylactic treatments using 
acupuncture or pharmacological medicine in the past 
3 months; and (4) provided written informed consent.
Exclusion criteria
Patients will be excluded if they have (1) tension-type 
headache, cluster headache or other primary headaches; 
(2) relatively severe systemic diseases (cardiovascular 
disease, acute infectious disease, haematopathy, endocr-
inopathy, allergy or methysis); (3) headache caused by 
otorhinolaryngology diseases or intracranial patholog-
ical changes; (4) secondary headache or other neurolog-
ical diseases; or (5) pregnancy, lactation or insufficient 
contraception.
randomisation and allocation concealment
The randomisation will be performed by the Research 
Centre of Clinical Epidemiology, Peking University Third 
Hospital. A block randomisation method (with a block 
size of four) will be used to generate the random allo-
cation sequence; predetermined computer-generalised 
randomisation opaque sealed envelopes will be used to 
ensure the allocation concealment. The opaque sealed 
envelopes, with the participant’s screening order printed 
outside and randomly assigned group printed inside, will 
be numbered consecutively and connected into a strain. 
Researchers will enrol the eligible participants after 
screening, then separate and open each envelope from 
the strain in the sequence corresponding to the partici-
pant’s screening order, and assign the eligible participant 
into either the treatment group or control group.
blinding and informed consent
In this study, the participants will be informed that they 
will have a 50% chance of being allocated to receive either 
of the two treatments: verum acupuncture plus placebo 
medication in the treatment group, or sham acupuncture 
plus real medication (topiramate) in the control group. 
The placebo medication will be identical to the real medi-
cation (topiramate) and sham acupuncture will produce 
the same stimulation as the verum acupuncture. Hence, 
participants will be blinded to their group allocation. 
The credibility of blinding will be tested at the beginning 
and end of the treatment phase (week 1 and week 12). 
Furthermore, outcome assessors and personnel involved 
in data collection and data analysis will be blinded to 
participants’ group allocation throughout the entire trial. 
The acupuncturist cannot be blinded due to the nature of 
the intervention, but they will be trained not to commu-
nicate with participants or outcome assessors regarding 
treatment procedures and responses.
Table 1 Schedule of enrolment, interventions and assessments
Study period
Enrolment 
(screening)
Allocation
(baseline) Treatment Follow-up (endpoint)
Time point Week −4 Week −1 Week 0 Week 1 Week 12 Week 13 Week 24
Enrolment
  Eligibility screen × 
  Informed consent × 
  Allocation ×
Interventions
  Treatment group
  Control group
Assessments
  Headache diary
  MIDAS × × × 
  MSQ × × × 
  HIT-6 × × × 
  STAI-T × × × 
  BDI-II × × × 
  Blinding/credibility 
test
× × 
  Adverse event
  Laboratory test* × ×  ×
*The laboratory test includes complete blood count and differential count, absolute neutrophil count, aspartate aminotransferase, alanine 
aminotransferase, total bilirubin, blood urea nitrogen, creatinine, albumin and coagulation test.
BDI-II, Beck Depression Inventory-II; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment; MSQ, Migraine-Specific Quality 
of Life Questionnaire; STAI-T, State-Trait Anxiety Inventory-trait.
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Intervention
The acupuncture treatment protocol was determined 
according to records in ancient and modern books and 
results of previous research on acupuncture treatment 
for chronic migraine.26 All participants will go through 
a standardised interview and be provided with details of 
the study. The acupuncturists who deliver treatments for 
both groups are registered with the Ministry of Health 
of the People’s Republic of China as Chinese medicine 
practitioners, and have more than 20 years of clinical 
experience. Before the trial begins, all acupuncturists 
will receive special training regarding the purpose and 
standard procedure of the trial, treatment strategies and 
quality control. The treatment details will be fully docu-
mented in accordance with the Standard Protocol Items 
for Randomized Trials Standards for Reporting Interven-
tions in Controlled Trials of Acupuncture (STRICTA)34 
and good clinical practice guidelines.
All participants will receive treatment for 12 weeks. 
In the treatment group, participants will receive three 
acupuncture sessions each week, together with placebo 
medication. In the control group, participants will be 
given medicine (topiramate) and three sessions of sham 
acupuncture each week.
Each acupuncture session (both verum and sham 
acupuncture) will last for 30 min. Sterilised, single-use 
needles (Hwato Needles, made in Suzhou, China) will be 
used for acupuncture in this trial. The number of needles 
will be no more than 10 in each session for both groups. 
Thirty-gauge (0.3 mm in diameter) needles with 40 mm in 
length will be used for limb points and 32-gauge (0.25 mm 
in diameter) needles with 25 mm in length will be used 
for head points. All needles will be inserted 10–15 mm in 
depth and manually manipulated with rotation methods 
to produce a characteristic sensation known as De Qi 
(feeling of needle sensation that refers to the tenseness 
around the needle felt by the practitioner and numbness, 
distension, soreness and heaviness around the point felt 
by the participant).
The placebo medication will be made by Xi’an Janssen 
Pharmaceutical and will have the exact same appearance 
as the real medicine (topiramate). During the titration 
period, participants will receive topiramate 25 mg/day 
at bedtime for 1 week, followed by a weekly increase of 
25 mg up to either 100 mg/day of topiramate or to the 
maximal tolerated dose. Starting in week 2, topiramate 
will be given daily in equally divided twice daily doses. 
During the maintenance period, a stable topiramate dose 
of at least 50 mg/day will be required. All participants 
will be permitted to treat acute headaches as required; 
ibuprofen will be recommended to all participants as 
their first choice for acute medication. The name and 
dosage of these medications will be recorded in the head-
ache diaries.
The points used in the treatment group
The main points used for all participants in the treatment 
group are: GV20 (Baihui), GV24 (Shenting), bilateral 
GB13 (Benshen), bilateral GB8 (Shuaigu) and bilateral 
GB20 (Fengchi).
Additional two points may be chosen according to 
syndrome differentiation of meridians: Shaoyang head-
ache (TE-GB): TE5 (Waiguan) and GB34 (Yanglingquan); 
Yangming headache (LI-ST): LI4 (Hegu) and ST44 
(Neiting); Taiyang headache (SI-BL): BL60 (Kunlun) 
and SI3 (Houxi); Jueyin headache (PC-LR): LR3 (Taic-
hong) and GB40 (Qiuxu) (see figure 2).
The points used in the control group
The sham acupuncture will be conducted using the same 
methods as verum acupuncture but on different points, 
including two points on the arms and three points on 
the legs. These points were defined as unrelated to head-
ache based on a vast amount of Chinese medicine refer-
ence books and the consensus of clinical experiences of 
acupuncture experts. The sham points are bilateral LI15 
(Jianyu), bilateral PC3 (Quze), bilateral GB35 (Yangjiao), 
bilateral LR7 (Xiguan) and bilateral ST37 (Shangjuxu) 
(see figure 2).
outcome measures
The primary outcome measure will be the reduction of 
monthly headache days, which will be calculated using the 
data collected from the second to the fourth headache 
Figure 1 Flow diagram of the study procedure.
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diaries (treatment phase) compared with the first diary 
(collected in the screening period, 4 weeks before the 
beginning of the trial). Headache diaries are designed to 
record the details of migraine attacks, including duration, 
frequency, location, intensity, presence of aura, causality 
of the headache and concomitant symptoms in each 
migraine attack. The participants will also document the 
number of days with acute headache medication intake 
(including name, dosage, time of taking medicine, time 
of pain relief and side effects of analgesic drugs) for each 
migraine attack and study medication received in the 
headache diaries.
The secondary outcome measures include (1) reduc-
tion of the number of days with acute headache medi-
cations, from the second to the fourth diaries compared 
with that from the first diary (screening period); (2) 
change of Migraine Disability Assessment (MIDAS)35 
scores from baseline to endpoints (week 12 and week 
24); (3) change of Migraine-Specific Quality of Life Ques-
tionnaire (MSQ)36 scores from baseline to endpoints; 
(4) change of Headache Impact Test (HIT-6)37 scores 
from baseline to endpoints; (5) change of State-Trait 
Anxiety Inventory-trait (STAI-T)38 scores from baseline to 
endpoints; and (6) change of Beck Depression Invento-
ry-II (BDI-II)39 scores from baseline to endpoints.
These five questionnaires will be repeatedly assessed 
at week 0, week 12 and week 24 by one physician who is 
blinded to group allocation to ensure consistency.
Detailed time points of each outcome assessment are 
provided in table 1.
safety assessments
Safety assessments will include the incidence of AEs, clin-
ical laboratory tests (including urine pregnancy test), vital 
sign measurements and physical examination findings. 
The clinical laboratory tests will include haematology, 
chemistry and urinalysis tests. Vital sign measurements 
will include sitting blood pressure, heart and respiration 
rate, and body temperature. AEs are defined as negative 
or unintended clinical manifestations following the treat-
ment. Our investigators will collect information regarding 
AEs throughout the treatment and follow-up phases. 
Participants will be instructed to report any abnormal 
reactions or uncomfortable feelings experienced to any 
researcher. All unexpected AEs will be recorded with 
details in the Case Report Forms (CRF), including time 
of occurrence, degree of AE and possible causes. Partic-
ipants with mild and moderate AEs will be treated for 
their symptoms and closely monitored as necessary by the 
researcher. Severe AEs will be reported to the Research 
Ethics Committee, which will provide medical advice 
to the research team within 48 hours, and the Research 
Ethics Committee will determine whether a termination 
of the trial is required.
data management
All researchers including the acupuncturists, outcome 
assessors, data collector, data manager, data entry 
personnel and statistician will receive special training 
regarding the standard procedure and data manage-
ment. During the recruitment period, our data collector 
Figure 2 Schematic sites of acupuncture points in treatment group and control group.
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will record the baseline characteristics of participants in 
CRFs, and all data will be checked by the data manager.
Upon the completion of the treatment and follow-up 
phases, all participants’ data will be completed and 
recorded on the original CRFs and then entered into 
Excel spreadsheets by two data entry personnel inde-
pendently, following which the data manager will 
cross-check two data sets to ensure accuracy. If any incon-
sistencies are noted, corrections will be made according 
to, and marked on, the original CRFs. All data will be 
managed in accordance with the Data Protection Act of 
1998.40 All hard copy documents related to the research 
will be saved in a locked filing cabinet, while electronic 
documents will be stored in a special computer that will 
remain password protected and accessible only to the 
principal investigators. All research documents, including 
both the hard copy documents and electronic files, will be 
saved for at least 5 years after publication. If readers have 
any questions regarding our published data, they will be 
permitted to contact our first author or corresponding 
author to obtain the original data.
sample size calculation
In a previous study,33 the reduced number of chronic 
migraine days after treatment was 10.5±2.8 days in the 
acupuncture group and 7.8±3.6 days in the control 
group. PASS V.11 software (NCSS, Kaysville, Utah, USA) 
was used to calculate that, based on 80% power to detect a 
significant difference (α=0.05, two sided), 26 participants 
will be required for each group. Allowing for a 10% with-
drawal rate, we plan to include a total of 60 participants 
with 30 participants in each group.
statistical analysis
Data analysis will be performed by statisticians who are 
blinded to the entire allocation and intervention process. 
The statisticians are affiliated with the Research Centre of 
Clinical Epidemiology, Peking University Third Hospital, 
which is one of the most authoritative statistics centres in 
the country. All data in this trial will be assessed using the 
SPSS statistical software package (V.22.0) (International 
Business Machines). The intention-to-treat population 
will be the main set used for all efficacy analyses. The 
per-protocol set will be used for the sensitivity and consis-
tency analysis to compare the results from the inten-
tion-to-treat set. The per-protocol set will consist of the 
participants who have completed the trial without major 
protocol violations and will finally provide all outcome 
measures. The last observation carried forward method 
will be used to process the missing data for the primary 
outcome. Two-tailed analyses will be conducted, with the 
level of statistical significance defined as p<0.05.
Demographic characteristics and baseline measure-
ments of the variables of each group will be summarised. 
Continuous variables will be shown as the means±SDs 
with a 95% CI. Independent two-sample t-tests or the 
Mann-Whitney U test will be performed to compare the 
continuous data from each group. For dichotomous 
or categorical data, frequency and percentage will be 
presented, and the difference between groups will be 
compared using the Χ2 test or the Fisher’s exact test.
The mean change of the monthly headache days is 
the primary outcome measure of this study. One sample 
of the Kolmogorov-Smirnov test will be used to test the 
normal distribution of continuous variables. Contin-
uous variables will be shown as the means±SDs if they are 
normally distributed or as medians with IQRs if they are 
not normally distributed. If the measurement data are 
normally distributed, independent two-sample t-tests will 
be used for comparisons among the groups, while paired 
t-tests will be used for within-group comparisons. If the 
measurement data have a non-normal distribution, the 
Mann-Whitney U test will be used for comparisons among 
the groups, while Wilcoxon signed-ranks test will be used 
for within-group comparisons.
The secondary outcome measures include the mean 
change of days with acute headache medications, and the 
changes of MIDAS, MSQ, HIT-6, STAI-T and BDI-II scores 
from baseline to endpoints in the study. The secondary 
outcome measures will be analysed following the same 
methods used for the primary outcome measure analysis.
AEs will be analysed in the safety set, which consists of 
all participants who received at least one treatment in this 
trial. AEs will be pooled for each organ system class and 
preferred term, and then the percentage of patients with 
AEs and percentage of patients with laboratory AEs will 
be summarised with descriptive statistics.
Patient and public involvement
This trial was designed to evaluate the add-on effects of 
acupuncture for migraine prevention. In clinical prac-
tice, the prevention of episodic migraine is considered 
more important than the treatment for acute attacks for 
patients with chronic migraine. Adding acupuncture to 
conventional therapy may increase the effectiveness in 
terms of preventing episodic migraine, hence significantly 
improve patients’ quality of life. The outcome measures 
used in this study were commonly used in clinical trials of 
chronic migraine, and considered as important endpoints 
in our clinical practice. Patients with chronic migraine in 
our clinical department were consulted prior to the trial 
design, in particular, the treatment frequency and dura-
tion of this trial were summarised from our clinical experi-
ence and patients’ feedback. The participants of this trial 
will be recruited from our clinical department. However, 
those who were involved in the consultation related to 
the trial design will not be included as trial participants. 
Upon the completion of this trial, a journal article manu-
script will be prepared to present the trial results. Once 
this manuscript is published, a brief summary of results 
using plain language will be sent to all trial participants. 
The burden of intervention will not be assessed by trial 
participants.
Ethics and dissemination
The trial protocol is in accordance with the princi-
ples of the Declaration of Helsinki41 and was approved 
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by the Research Ethical Committee of Beijing Hospital 
of Traditional Chinese Medicine Affiliated to Capital 
Medical University on 21 July 2017 (Ethics Reference 
No: 2017BL-045-01) (online supplementary file 2). This 
trial was registered at ISRCTN (ID: ISRCTN13563102). 
Each participant will be provided information regarding 
the study protocol. Written informed consent will be 
obtained from every participant.
dIsCussIon
This trial is designed as a single-blinded, double-dummy 
RCT. The completion of this trial will provide detailed and 
accurate evidence of the efficacy and safety of acupunc-
ture for chronic migraine prophylaxis. The advantages of 
the trial design are shown in the following three aspects.
double-dummy design and blinding
To determine an appropriate control method is crucial 
for the assurance of the methodological quality of an 
RCT. Considering that acupuncture is a physical interven-
tion, to design an inert placebo control for acupuncture is 
challenging. Although using placebo needles on effective 
acupuncture points has been applied in previous clinical 
trials, it was found that this approach may induce a wide 
range of peripheral, segmental and central physiological 
responses to an unpredictable degree.42–44
The method of needling non-acupuncture points with 
minimal acupuncture (using fine needles to penetrate 
the skin superficially) has been employed as a sham 
control in previous studies of migraine.29 45 However, 
some researchers have advised that involving sham 
acupuncture as the control tends to have more ‘negative’ 
results compared with the design of verum acupuncture 
versus other types of control, such as placebo acupunc-
ture (non-insertion) and non-acupuncture treatment.46 47 
In addition, sham acupuncture produced a larger effect 
size than the pharmacological placebo compared with 
non-treatment.48 49 It has been suggested that sham 
acupuncture appears to comprise a true placebo effect 
and other physiological effects from needle insertion.50 
Therefore, RCTs utilising sham acupuncture as a control 
can only answer the question of acupuncture point speci-
ficities or stimulation technique specificities, but not effi-
cacy.51 52
Further, the methods of using non-penetrating placebo 
needles or superficial needling may not be practical 
among the Chinese population, considering that Chinese 
people generally expect that certain sensations should be 
achieved in acupuncture treatment. Therefore, we chose 
the method of needling ineffective acupuncture points 
as the sham acupuncture intervention. This method has 
been used in previous clinical trials of migraine with the 
advantage of minimising bias caused by unblinding of 
patients.28 53
Based on careful consideration of control methods’ 
selection, we determined a double-dummy type design 
in this study. Both groups in this trial will receive real 
treatments (either real acupuncture or real medication). 
This approach will encourage a better compliance of 
participants. A medication proven effective for chronic 
migraine and sham acupuncture (ineffective acupunc-
ture points) were chosen as the treatments given to the 
control group in our study. Compared with the design in 
which a positive drug is given without sham acupuncture 
as a control, our design may rule out the possibility of a 
placebo effect caused by the strong belief in acupuncture 
among Chinese population.
Genuine double-blinding is difficult in acupuncture 
trials since the acupuncturists must be aware of the partici-
pant’s group allocation to deliver the treatment. Although 
some efforts have been made to design a double-blinding 
placebo acupuncture device, there has not been enough 
evidence to support the use of such a device.54
In this trial, all participants will be blinded through 
the double-dummy design, and all outcome assessors 
and statisticians will be kept unaware of group allocation 
throughout the whole process. Only the acupuncturists 
will not be blinded but they will be required to minimise 
conversation about the treatment details.
selection of medication and acupuncture points
Topiramate, as an antiepileptic medication (AED), is 
Food and Drug Administration approved and widely 
accepted as a treatment for chronic migraine preven-
tion. Several placebo-controlled randomised clinical 
trials have shown that topiramate significantly reduced 
the number of migraine headache days in patients with 
chronic migraine.19 55 56 Topiramate is considered safe, 
effective and generally well tolerated for the prophy-
lactic treatment of chronic migraine. Therefore, we 
will compare the efficacy of acupuncture with topira-
mate, which was chosen as the standard drug therapy. 
Migraineurs are more sensitive to topiramate-related 
AEs than patients with epilepsy. The most common AEs 
associated with topiramate are paraesthesia and cogni-
tive problems. Paraesthesia commonly occurs in early 
topiramate treatment but is rarely a cause for treatment 
discontinuation. Cognitive syndromes occur much less 
frequently than paraesthesia but are more troublesome 
and may cause termination treatment. AEs of topiramate 
are generally of mild or moderate severity and tend to be 
dose dependent.57
Thus far, the particular mechanism by which acupunc-
ture affects migraine has not been fully revealed. 
According to the gate control theory, once fine acupunc-
ture needles have been inserted into body points, A delta 
fibres may be stimulated to close the pain gates in the 
central nervous system, therefore the sensation of pain 
will not be perceived due to failure of reaching the thal-
amus.58 In addition, many researchers have held the view 
that acupuncture may influence calcium signalling and 
the opioid system. The acupuncture stimulations may 
produce and release endogenous opioids, which bind 
to opiate receptors in the brain and mediate analgesia 
through the descending pain inhibitory system.59
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Furthermore, the positive effect of acupuncture on 
migraine may not be owing to penetration of the tissues 
per se, but also due to the local stimulations on effective 
acupuncture points (perforation or touch).60 According 
to traditional Chinese medicine theory, an acupuncture 
point refers to a specific point on the body surface that 
is inactive when the body is in a healthy condition, but 
can be further activated by certain stimuli. Well-defined 
acupuncture point selection principles for practitioners 
to consider in clinical situations have been developed 
and used under the umbrella of the existence of acupoint 
specificity.61
Traditional acupuncture has its own diagnostic system 
for headaches, in which treatment should be individu-
alised (acupuncture points vary from person to person 
or from treatment to treatment). However, the absence 
of standardised approaches to acupuncture treatments 
obstructs data reproducibility across the discipline. With 
this in mind, we will use fixed and classic acupuncture 
points (standardised acupuncture with eight main points) 
in patients in the treatment group during every thera-
peutic session. A standardised acupuncture treatment 
protocol was obtained by the consensus of our acupunc-
ture expert panel. This standardisation makes our study 
replicable, consistent and as scientifically rigorous as 
possible. In addition, all patients will be classified into 
four subtype syndromes according to syndrome differen-
tiation of meridians,62 and two additional points will be 
chosen according to the syndrome type to fulfil the need 
for individualised treatment.
Comprehensive outcome measures
The monthly paper-and-pencil prospective headache diary 
includes (1) the use of any headache abortive medication; 
(2) headache occurrence; (3) headache intensity rated 
as average pain intensity for that day using a 0 to 10-point 
scale; (4) headache duration; and (5) associated symptoms 
for migraine. The number of monthly headache days will 
be the primary outcome measure in our study and has 
often been used as the primary outcome in previous studies 
of the chronic migraine population.33 63–65
With respect to secondary outcomes, we will measure 
acute headache medications, migraine-related disability, 
quality of life measures and psychological distress. 
The MIDAS scale is an ordinary rating scale to assess 
the migraine-related disability of a patient.35 Previous 
studies66 67 have illustrated that the MIDAS questionnaire 
is a valid, effective and sensitive tool to assess the migraine 
disability in a patient with chronic migraine. The HIT-6 
will be used to assess headache impact,37 68 which is a 
validated 6-item questionnaire covering content catego-
ries in pain, role functioning, social functioning, vitality, 
cognitive functioning and psychological distress. This 
questionnaire has been proven reliable and valid for 
use in the chronic migraine population.69 70 Quality of 
life in those with chronic migraine will be assessed using 
the MSQ, a 14-item questionnaire designed to measure 
how migraines affect or limit patients’ daily performance 
over the preceding 4 weeks across three domains36 71: role 
restrictive (RR), role preventive (RP) and emotional 
functioning (EF). Specifically, the RR domain assesses 
how migraines limit a sufferer’s daily social and work-re-
lated activities, the RP domain measures how migraines 
prevent such activities and the EF domain gauges the 
emotions associated with migraine. In addition, the 
chronic migraine population is often associated with 
significant psychological distress.72 Therefore, we will also 
apply the STAI-T39 73 and BDI-II38 to assess participants’ 
likely depression and distress symptoms.
It should be noted that our study has certain method-
ological limitation. To blind the patients, we will use a 
double-dummy design of verum acupuncture and placebo 
drug compared with topiramate and sham acupuncture. 
However, different types of placebos may have different 
non-specific effects. Higher placebo response rates are 
consistently reported with physical intervention such as 
acupuncture than those seen in trials using oral drugs.74 75 
Therefore, the placebo effects on patients produced by 
the placebo drug and sham acupuncture may differ, 
which could potentially affect the therapeutic outcomes.
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